Why ResMed’s Stock Slide Might Be a Mirror for the Medical Tech Industry’s Soul
Let’s cut straight to the chase: ResMed’s 20%+ stock drop in 2024 isn’t just a number. It’s a Rorschach test for investors. Are we looking at a wounded giant ripe for a comeback, or a cautionary tale about growth that’s outpaced its own skeleton? The answer, as always, lives in the messy intersection of numbers and narrative.
The Sleep Apnea Leviathan With an Identity Crisis
Here’s the surface story: ResMed dominates the $5B sleep apnea device market, connects hardware to the cloud like it’s 2077, and has a SaaS division that whispers promises of recurring revenue. But dig deeper, and the cracks show. Their core CPAP business is brilliant in theory—people literally can’t live without these machines—but commoditization looms. I’ve watched competitors like Philips bleed market share to cheaper alternatives. ResMed’s 57.4% gross margin? That’s a fortress… until insurers start demanding bids.
What fascinates me most is their dual listing dilemma. The ASX crowd gets a Silicon Valley-style growth story, but US investors see a mature medtech firm. This identity schism explains the valuation whiplash. Their 4.38x price-to-sales ratio feels ‘cheap’ until you ask: Cheap relative to what era? The 8.70x average was built during the pandemic’s telehealth mania. Reality has reset faster than their stock price.
The Cash Conundrum: Is Prudence Just Fear in Disguise?
Let’s talk about that -$624M net debt. On paper, it’s a safety blanket. But in my bones, I smell hesitation. Why hoard cash while buying back shares at depressed prices? ResMed could be stockpiling ammo for acquisitions—or they’re quietly terrified of macro headwinds. The 18% debt-to-equity ratio screams ‘safety first,’ but in a sector defined by innovation, playing defense feels risky. Medtronic didn’t become a titan by sitting on its hands.
And that 22.7% ROE? Gaudy, sure. But follow the breadcrumbs: 29.1% profit CAGR over three years. That’s not growth—it’s a sugar rush. How much of that came from cost-cutting versus real demand? Their SaaS unit’s margins are probably juicing the numbers. A dangerous game when healthcare IT is becoming its own arms race.
The Valuation Illusion: Why ‘Cheap’ Might Cost You
The bulls will wave the 13.6% revenue CAGR like a holy relic. I’ll counter: In medtech, 10%+ growth is table stakes. Their real test? Can the SaaS layer transform them from hardware vendors to data-driven healthcare architects? That’s the only path to re-rating. But here’s the rub—healthcare systems globally are broke. A $4,685M revenue giant selling cloud solutions to cash-strapped clinics? I see a Tesla-style ‘aspirational pricing’ problem.
If you’re pricing a CPAP machine at $1,000 and the SaaS add-on at $200/year, who’s the buyer? The US private pay model? That’s 15% of the world. Europe’s tenders? Good luck. This isn’t a tech problem—it’s a socioeconomic Gordian knot.
The Unspoken Truth Investors Fear
We’re all dancing around the elephant in the room: Sleep apnea is a lifestyle disease. CPAP adherence rates hover around 50%. What if the real growth driver isn’t medical need, but corporate wellness programs shaming executives into compliance? That’s a behavioral economics nightmare. ResMed’s hardware might be flawless, but they’re selling seatbelts to people who think airbags are enough.
Here’s my gut call: This stock won’t bottom until they pivot from ‘medical equipment company’ to ‘respiratory outcomes orchestrator.’ Until then, the 20% drop is just the first act. The question isn’t whether ResMed is cheap—it’s whether their business model belongs to a world that no longer exists. Buy if you’re a contrarian gambler. Watch if you respect gravity’s pull on overhyped healthcare plays.
